Sinopharm Group Co. Ltd (X2S) — Cash Flow-to-Debt Ratio
Sinopharm Group Co. Ltd (X2S) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2023, meaning its operating cash flow of €-2.63 Billion could theoretically repay 0% of its total liabilities (€304.58 Billion) in one year. See X2S FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sinopharm Group Co. Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Sinopharm Group Co. Ltd across 13 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Sinopharm Group Co. Ltd.
Annual Cash Flow-to-Debt Ratio for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year debt coverage analysis for Sinopharm Group Co. Ltd. Check Sinopharm Group Co. Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | €14.14 Billion | €256.20 Billion | ▲ +27.2% |
| 2024 | 0.04x | €11.55 Billion | €266.14 Billion | ▼ -33.5% |
| 2023 | 0.07x | €17.17 Billion | €263.08 Billion | ▼ -20.7% |
| 2022 | 0.08x | €20.96 Billion | €254.71 Billion | ▲ +108.5% |
| 2021 | 0.04x | €9.31 Billion | €235.76 Billion | ▼ -21.7% |
| 2020 | 0.05x | €11.15 Billion | €221.29 Billion | ▼ -48.2% |
| 2019 | 0.10x | €18.78 Billion | €192.95 Billion | ▲ +346.1% |
| 2018 | 0.02x | €3.65 Billion | €167.50 Billion | ▼ -19.6% |
| 2017 | 0.03x | €3.21 Billion | €118.27 Billion | ▼ -66.8% |
| 2016 | 0.08x | €9.26 Billion | €113.18 Billion | ▼ -39.9% |
| 2015 | 0.14x | €13.41 Billion | €98.55 Billion | ▲ +126.1% |
| 2014 | 0.06x | €5.56 Billion | €92.37 Billion | ▼ -6.4% |
| 2013 | 0.06x | €4.94 Billion | €76.84 Billion | — |